person · Reporting owner
Jemapete Christopher J
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BLUE BIOFUELS, INC.
Report date August 25, 2018 · Filed August 29, 2018
Section 16 reporting ended · disclosed 2018-08-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to purchase Common Stock, $0.001 par valueSEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2023-05-15 | Direct | 0 |
Reported balance
After 2018-08-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-25 · Other · Disposed 1,000,000 · Balance 0 F1: Pursuant to an agreement between the reporting person and the issuer, the reporting person agreed to forfeit the warrant for good and valuable consideration. |
| Warrant to purchase Common Stock, $0.001 par valueSEC Table II · derivative / convertible security · Conversion / exercise price $0.10 · Expires 2023-05-15 | IndirectHeld in name of spouse | 0 |
Reported balance
After 2018-08-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-08-25 · Other · Disposed 1,000,000 · Balance 0 F2: Pursuant to an agreement between the reporting person's spouse and the issuer, the reporting person's spouse agreed to forfeit the warrant for good and valuable consideration. |
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 6,250,000 |
Reported balance
Holding disclosure · report date 2018-08-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,250,000 |
| Common Stock, par value $0.001SEC Table I · non-derivative | IndirectHeld in name of spouse | 6,250,000 |
Reported balance
Holding disclosure · report date 2018-08-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,250,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an agreement between the reporting person and the issuer, the reporting person agreed to forfeit the warrant for good and valuable consideration.
F2: Pursuant to an agreement between the reporting person's spouse and the issuer, the reporting person's spouse agreed to forfeit the warrant for good and valuable consideration.
Gene Biotherapeutics, Inc.
Report date March 31, 2021 · Filed April 28, 2021
Section 16 reporting ended · disclosed 2021-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000,000 |
Reported balance
Holding disclosure · report date 2021-03-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,000,000 F1: Based on the issuer's annual report on Form 10-K, filed with the Securities and Exchange Commission on April 23, 2020, there were 49,622,154 shares of the issuer's common stock outstanding as of March 31, 2021. Accordingly, as of March 31, 2021, the reporting person beneficially owned less than 10% of the issuer's outstanding common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on the issuer's annual report on Form 10-K, filed with the Securities and Exchange Commission on April 23, 2020, there were 49,622,154 shares of the issuer's common stock outstanding as of March 31, 2021. Accordingly, as of March 31, 2021, the reporting person beneficially owned less than 10% of the issuer's outstanding common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2021 Filed Mar 18, 2021 14:08 UTC | Gene Biotherapeutics, Inc. CRXM · Entity 139980 | PurchaseCommon Stock | 200,000 | $0.40 | $80,400.00 |
DisclosureSEC source: 0001493152-21-006314 · ownership.xml · nonDerivative · entry 2 Jemapete Christopher J · CIK 0001741021 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000,000 F2 · price: Represents the weighted average purchase price for 16 transactions effected on March 17, 2021, with purchase prices per share ranging from $0.0378 to $0.0425. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 14:08 UTC | Gene Biotherapeutics, Inc. CRXM · Entity 139980 | PurchaseCommon Stock | 300,000 | $0.04 | $11,970.00 |
DisclosureSEC source: 0001493152-21-006314 · ownership.xml · nonDerivative · entry 1 Jemapete Christopher J · CIK 0001741021 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800,000 F1 · price: Represents the weighted average purchase price for two transactions effected on March 16, 2021, with purchase prices per share ranging from $0.0378 to $0.04. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 25, 2018 Filed Aug 29, 2018 17:08 UTC | BLUE BIOFUELS, INC. ALLM · Entity 2467 | OtherWarrant to purchase Common Stock, $0.001 par value · Derivative | 1,000,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001493152-18-012697 · ownership.xml · derivative · entry 4 Jemapete Christopher J · CIK 0001741021 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held in name of spouse Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2023-05-15 F2 · kind: Pursuant to an agreement between the reporting person's spouse and the issuer, the reporting person's spouse agreed to forfeit the warrant for good and valuable consideration. Read SEC document |
| August 25, 2018 Filed Aug 29, 2018 17:08 UTC | BLUE BIOFUELS, INC. ALLM · Entity 2467 | OtherWarrant to purchase Common Stock, $0.001 par value · Derivative | 1,000,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001493152-18-012697 · ownership.xml · derivative · entry 3 Jemapete Christopher J · CIK 0001741021 · Former 10% Owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2023-05-15 F1 · kind: Pursuant to an agreement between the reporting person and the issuer, the reporting person agreed to forfeit the warrant for good and valuable consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.